Company intelligence / Profile preview

Hangzhou Clongene Biotech

Hangzhou, Zhejiang, Chinaclongene.com ↗

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

Clongene’s COVID‑19 antigen rapid test has been evaluated in clinical studies and is commercially available globally. The company’s IVD reagents have received regulatory approvals including NMPA China, FDA US 510(k), CE EU mark. No therapeutics or drugs in clinical development—focus is on diagnostics.

Therapeutic areas: OncologyEndocrinologyImmunologyOtherPsychiatryInfectious Diseases
Modalities: AntibodyMonoclonal antibodyPolyclonal antibodyRecombinant proteinEnzyme
Industry: Protein Biomarker Diagnostics

Partnerships

Sells to global distributors and partners with IVD manufacturers worldwide

Beyond the preview

Go deeper on Hangzhou Clongene Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou Clongene Biotech.

Explore the full profile